scPharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 136
- Market Cap
- $257.6M
- Introduction
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06167707
- Locations
- 🇺🇸
Elixia EPCT, LLC, Tampa, Florida, United States
Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study
- Conditions
- Heart Failure
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04593823
- Locations
- 🇺🇸
Heart Group of Eastern Shore, Fairhope, Alabama, United States
🇺🇸The Heart Center Research, LLC, Huntsville, Alabama, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04161482
- Locations
- 🇺🇸
Aventiv Clinical Research, Columbus, Ohio, United States
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
- Conditions
- Heart Failure
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03458325
- Locations
- 🇺🇸
Olive View - UCLA Medical Center, Sylmar, California, United States
🇺🇸Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
Product Design Clinical Performance Study of sc2Wear Furosemide Combination Product
- Conditions
- Heart Failure
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02804282
- Prev
- 1
- 2
- Next
News
FDA Expands Furoscix Approval to Include Edema Treatment in CKD Patients
• The FDA has approved scPharmaceuticals' supplemental New Drug Application for Furoscix, extending its use to treat edema in chronic kidney disease patients, with availability expected in April 2025. • Furoscix becomes the first subcutaneous loop diuretic approved for both heart failure and CKD patients, offering an at-home alternative to traditional IV diuretic therapy. • The approval was granted without requiring additional clinical studies, based on demonstrating adequate pharmacokinetic and pharmacodynamic equivalence to standard furosemide injection.
FDA Expands Furoscix Indication to Include NYHA Class IV Heart Failure Patients
• The FDA has approved scPharmaceuticals' supplemental New Drug Application (sNDA) for Furoscix, expanding its indication to include NYHA Class IV chronic heart failure patients. • This expansion allows Furoscix to be used in the most symptomatic heart failure patients, who experience the greatest limitations on physical activity, representing approximately 10% of all heart failure patients. • Furoscix offers a potential alternative to hospital admission or readmission for managing congestion due to fluid overload in adult patients with chronic heart failure. • Furoscix is designed for subcutaneous self-administration, offering an outpatient treatment option for heart failure patients.